NCT04691947已完成1 期
Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 2
- 主要终点
- To assess the safety and tolerability of the COVID-19 vaccine
研究概览
简要总结
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.
详细描述
This is a double-blind, double dose, parallel, randomized vaccination study. Each subject will receive in random order a double intramuscular dose of ERUCOV-VAC 3 µg/0.5 ml Vaccine, ERUCOV-VAC 6 µg/0.5 ml Vaccine or 0.5 ml of placebo Vaccine according to a sequence determined by randomization, on Day 0 (1st vaccination) and Day 21 (2nd vaccination).In total 34 healthy subjects of both genders will be monitored for one year in total, after Day 43 the study will be unblinded and the volunteers who took placebo vaccine will be released from the study. The most important evaluation will be performed on Day 43 after the first vaccine dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy Caucasian origin
- •age between 18 and 55 years
- •accepting not to participate in another COVID-19 vaccine study until the end of the study
- •volunteers who do not plan to get a child in the next one year; the volunteer and the partner should use a reliable form of contraception (abstinence, condom, birth control implant, birth control pills used or IUD used by the partner) during the study for at least 1 year
- •participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination
- •the outcome of the following examinations should be clinically insignificant: medical and surgical history (hypo-, hypertension, allergy, other diseases, major surgery, micturition, defecation, sleep, illness within the last 4 weeks prior to the start of the trial);
- •life style and habits (consumption of alcohol, nicotine, coffee, tea, coke, special diet, drug abuse) should be normal/acceptable
- •body temperature, pulse rate, blood pressure, respiratory rate and 12 lead ECG should be normal/acceptable.
- •physical examination (general state and abnormal findings per system: endocrine/metabolic, allergies, drug sensitivities, head, neck, eyes, ears, nose, throat, cardiovascular, respiratory, gastrointestinal, hepatic/biliary, urogenital, musculoskeletal, lymph nodes, skin, and neurological/psychiatric) should be normal/acceptable
- •laboratory examination (blood/serum examination: sodium, potassium, calcium, chloride, total protein, albumin, glucose, creatinine, BUN, uric acid, total bilirubin, direct and indirect bilirubin, lipid panel (total cholesterol, triglyceride, HDL, LDL), AST, ALT, GGT, ALP, haemoglobin, haematocrit, erythrocytes, leukocytes, platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT); HBsAg, HIV-Ab, HCV-Ab; urine examination: urine color, appearance, specific gravity, pH, protein, glucose, ketones, blood, leukocytes, bilirubin, urobilinogen, nitrites and sediment if erythrocytes or leukocytes are out of the limits ) should be normal/acceptable.
- •antiSARS CoV 2 total antibody (including COVID-19 IgG and/or IgM) negative in serum.
- •drug screening negative (amphetamines, cannabinoids, benzodiazepines, cocaine, opioids, barbiturates)
- •normal body weight in relation to height and age according to BMI (accepted range 18.5 and 30 kg/m2)
排除标准
- •women with a positive blood (β-HCG) pregnancy test
- •lactating women
- •history of COVID-19 infection or showing COVID-19 infection symptoms
- •having had contact to people with known COVID-19 infection in the last 14 days
- •having fever (> 37.4oC in the last 24 hours), dry cough or feeling tired and having aches and pains, nasal congestion, runny nose, sore throat and diarrhea.
- •positive real time RT-PCR COVID-19 test.
- •persons with autoimmune diseases
- •allergic diathesis or any clinically significant allergic disease (i.e. asthma)
- •any condition that might impair the immune response
- •recent or current immunosuppressive medication
- •any other vaccine application 30 days before the first dose
结局指标
主要结局
To assess the safety and tolerability of the COVID-19 vaccine
时间窗: 43 days
The number and proportion of subjects with adverse events observed until Day 43 post 1st vaccination are declared to be primary target variables.
次要结局
- TNF-alpha Levels(12 months)
- Interferon Levels(12 months)
- Serum IgG antibody Levels(12 months)
- Neutralizing Antibodies Levels(12 months)
- Interleukine Levels(12 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to PlaceboCOVID-19 VaccineNCT04838080Kocak Farma38
已完成
2 期
Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19COVID-19NCT04824391Health Institutes of Turkey250
撤回
1 期
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenHIV SeronegativityHIV InfectionsNCT00000809National Institute of Allergy and Infectious Diseases (NIAID)
已完成
1 期
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy VolunteersCOVID-19NCT05148962Gritstone bio, Inc.45
已完成
1 期
PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax VaccineAnthraxNCT02239172Fraunhofer, Center for Molecular Biotechnology30